List of False Positives and False Negatives on CT CT Diagnosis Histopathological Diagnosis Metastasis Grade III Astrocytoma Meningioma Oligoastrocytoma Cerebral abscess Grade III Astrocytoma GBM Tuberculosis Choroid plexus
carcinoma Craniopharyngioma Choroid plexus
carcinoma Glioblastoma multiforme Acute infarct Grade II glioma Table 7.
Identification of five new families strengthens the link between childhood choroid plexus
carcinoma and germline TP53 mutations.
Fiona Doetsch at the Biozentrum of the University of Basel has now shown that the choroid plexus
is a key component of the stem cell niche, whose properties change throughout life and affect stem cell behavior.
Cauterization of the choroid plexus
was attempted in one case.
We classified the present case as congenital hydrocephalus based on the bird's age, history, the course of the clinical signs, and histopathologic observations, even though no obstructions or choroid plexus
alterations were detected.
Combined endoscopic third ventriculostomy and choroid plexus
cauterization as primary treatment of hydrocephalus for infants with myelomeningocele: Long-term results of a prospective intent-to-treat study in 115 East African infants.
Approximately two-thirds of the total CSF volume is generated by the choroid plexus
, with the remainder produced by extra-choroidal tissue.
A choroid plexus
papilloma is usually midline without temporal bone destruction.
American Institute of Ultrasound in Medicine: Basic elements of a standard second-trimester fetal anatomy scan * Focus Structures Head, face, neck Cerebellum Choroid plexus
Cisterna magna Lateral cerebral ventricles Midline falx Cavum septi pellucidi Upper lip Nuchal fold** Chest 4-chamber view Outflow tracts, if feasible Abdomen Stomach: presence, size, and situs Kidneys Bladder Umbilical cord insertion site (into fetal abdomen) Umbilical cord vessel number Spine Cervical, thoracic, lumbar, and sacral Extremities Legs and arms: presence or absence Sex * A more detailed fetal anatomic examination may be indicated if an abnormality is found on the standard examination.
Using breakthrough proprietary microencapsulation technology, IMMUPEL(TM), which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus
cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, stroke, and hearing loss.
The most common histologies by age are as follows: in the less than 1 year old age group, tumors arising in the choroid plexus
(33%) were more frequent.
It often remains attached to the choroid plexus
and can vary in size from 0.